CLRB News and Press, Cellectar Biosciences Inc. From 01/14/20

The following slide deck was published by Cellectar Biosciences, Inc. in conjunction with this Read more ...

FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Da...

Humana ( HUM ) had a pretty decent 2019 as its stock rallied over 30 percent, delivering solid returns to investors. I don't generally cover non-pharma stocks, but this rally, coupled with some interesting news lately, has made HUM an interesting stock to watch. While the company made stride...

FLORHAM PARK, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has appointed Dr. Igor Grachev as...

aTyr Pharma (NASDAQ: LIFE ) +63%  on Kyorin Pharma deal . More news on: aTyr Pharma, Inc., Town Sports International Holdings, Inc., Pulmatrix, Inc., Stocks on the move, Read more ...

Thinly traded nano cap Cellectar Biosciences (NASDAQ: CLRB ) perks up  11%  premarket on average volume in reaction to Orphan Drug designation in the U.S. for CLR 131 for slow-growing type of non-Hodgkin lymphoma called lymphoplasmacytic lymphoma (LPL). More news on: Cellecta...

FLORHAM PARK, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Adm...

Dosing is underway in a Phase 2 registrational trial in China evaluating I-Mab Biopharma's TJ202/MOR202, a fully human monoclonal antibody targeting a protein found on the surface of cancer cells called CD38, in patients with relapsed/refractory multiple myeloma (MM). The company in-lice...

FLORHAM PARK, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president ...

30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile Additional data in patients receiving higher fractionated doses of CLR 131 anticipated in January FLORHAM PARK, N.J., Dec. 16, 2019 (GLOBE NEWSWIRE) -...